Talat Imran - Dec 16, 2023 Form 4 Insider Report for Rani Therapeutics Holdings, Inc. (RANI)

Role
Chief Executive Officer, Director
Signature
Talat Imran
Stock symbol
RANI
Transactions as of
Dec 16, 2023
Transactions value $
$0
Form type
4
Date filed
12/19/2023, 04:05 PM
Previous filing
Dec 7, 2023
Next filing
Mar 22, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RANI Stock Option (Right to Buy) Disposed to Issuer -480K -83.33% 95.9K Dec 16, 2023 Class A Common Stock 480K $5.44 Direct F1, F2, F3
transaction RANI Stock Option (Right to Buy) Award +480K 480K Dec 16, 2023 Class A Common Stock 480K $2.84 Direct F1, F3
transaction RANI Stock Option (Right to Buy) Disposed to Issuer -154K -58.33% 110K Dec 16, 2023 Class A Common Stock 154K $13.21 Direct F2, F3, F4
transaction RANI Stock Option (Right to Buy) Award +154K 154K Dec 16, 2023 Class A Common Stock 154K $2.84 Direct F3, F4
transaction RANI Stock Option (Right to Buy) Disposed to Issuer -272K -37.5% 453K Dec 16, 2023 Class A Common Stock 272K $19.56 Direct F2, F3, F5
transaction RANI 271875 Award +272K 272K Dec 16, 2023 Class A Common Stock 272K $2.84 Direct F3, F5
transaction RANI Stock Option (Right to Buy) Disposed to Issuer -31.3K -39.58% 47.7K Dec 16, 2023 Class A Common Stock 31.3K $9.44 Direct F2, F3, F6
transaction RANI Stock Option (Right to Buy) Award +31.3K 31.3K Dec 16, 2023 Class A Common Stock 31.3K $2.84 Direct F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 27, 2023.
F2 The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date.
F3 The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options.
F4 The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 22, 2022.
F5 The shares subject to the option vest as follows: 25% of the shares subject to the option vests on June 14, 2022; and 1/48th of the shares subject to the option vest monthly over the remaining three years.
F6 The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from June 17, 2021.